Larimar Therapeutics (LRMR) Stock Forecast, Price Target & Predictions
LRMR Stock Forecast
Larimar Therapeutics stock forecast is as follows: an average price target of $17.00 (represents a 313.12% upside from LRMR’s last price of $4.12) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
LRMR Price Target
LRMR Analyst Ratings
Buy
Larimar Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 17, 2024 | Edward White | H.C. Wainwright | $15.00 | $4.28 | 250.47% | 264.52% |
Oct 30, 2024 | Samantha Semenkow | Citigroup | $14.00 | $8.46 | 65.48% | 240.22% |
Oct 03, 2024 | Laura Chico | Wedbush | $22.00 | $6.29 | 249.76% | 434.63% |
Apr 03, 2024 | Joori Park | Leerink Partners | $25.00 | $7.57 | 230.25% | 507.53% |
Dec 13, 2022 | Citigroup | $4.00 | $3.97 | 0.76% | -2.79% |
Larimar Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 3 | 4 |
Avg Price Target | $15.00 | $17.00 | $19.00 |
Last Closing Price | $4.12 | $4.12 | $4.12 |
Upside/Downside | 264.52% | 313.12% | 361.73% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Dec 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Oct 30, 2024 | Citigroup | Buy | Buy | Hold |
Oct 15, 2024 | Oppenheimer | Outperform | Initialise | |
Oct 03, 2024 | Wedbush | Outperform | Initialise | |
Oct 02, 2024 | H.C. Wainwright | Buy | Initialise | |
May 22, 2024 | Citigroup | Buy | Buy | Hold |
May 21, 2024 | William Blair | Outperform | Outperform | Hold |
May 21, 2024 | William Blair | Hold | Hold | Hold |
Dec 13, 2022 | Citigroup | Neutral | Initialise | |
Sep 19, 2022 | William Blair | Outperform | Upgrade |
Larimar Therapeutics Financial Forecast
Larimar Therapeutics Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Larimar Therapeutics EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Larimar Therapeutics Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-27.98M | $-27.71M | $-27.29M | $-27.38M | $-29.30M | $-27.23M | $-24.61M | $-22.27M | $-20.50M | $-23.91M | $-19.48M |
High Forecast | $-27.98M | $-27.71M | $-27.29M | $-27.38M | $-29.30M | $-27.23M | $-24.61M | $-17.96M | $-17.67M | $-23.91M | $-19.48M |
Low Forecast | $-27.98M | $-27.71M | $-27.29M | $-27.38M | $-29.30M | $-27.23M | $-24.61M | $-25.86M | $-21.91M | $-23.91M | $-19.48M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Larimar Therapeutics SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Larimar Therapeutics EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.44 | $-0.43 | $-0.43 | $-0.43 | $-0.46 | $-0.43 | $-0.39 | $-0.35 | $-0.32 | $-0.37 | $-0.31 |
High Forecast | $-0.44 | $-0.43 | $-0.43 | $-0.43 | $-0.46 | $-0.43 | $-0.39 | $-0.28 | $-0.28 | $-0.37 | $-0.31 |
Low Forecast | $-0.44 | $-0.43 | $-0.43 | $-0.43 | $-0.46 | $-0.43 | $-0.39 | $-0.41 | $-0.34 | $-0.37 | $-0.31 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Larimar Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
IMRX | Immuneering | $1.73 | $17.50 | 911.56% | Buy |
SPRO | Spero Therapeutics | $1.04 | $10.00 | 861.54% | Buy |
STRO | Sutro Biopharma | $2.09 | $13.00 | 522.01% | Buy |
CABA | Cabaletta Bio | $2.75 | $16.33 | 493.82% | Buy |
KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
CHRS | Coherus BioSciences | $1.71 | $6.00 | 250.88% | Hold |
CELC | Celcuity | $12.55 | $39.00 | 210.76% | Buy |
KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
SNDX | Syndax Pharmaceuticals | $13.63 | $31.67 | 132.36% | Buy |
ALEC | Alector | $1.89 | $4.00 | 111.64% | Buy |
DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
BOLT | Bolt Biotherapeutics | $0.54 | $1.00 | 85.19% | Hold |
MRUS | Merus | $44.90 | $81.25 | 80.96% | Buy |
PCVX | Vaxcyte | $89.86 | $148.80 | 65.59% | Buy |
CNTA | Centessa Pharmaceuticals | $17.60 | $23.25 | 32.10% | Buy |
IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |